A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, open-label, phase II study to evaluate the efficacy and
safety of anti-PD-1 antibody Penpulimab (AK105) combined with chemotherapy ± anlotinib
hydrochloride in the first-line treatment of patients with advanced nasopharyngeal carcinoma.